TrialStem cells translational medicine2022

Phase I/IIa Feasibility Trial of Autologous Quality- and Quantity-Cultured Peripheral Blood Mononuclear Cell Therapy for Non-Healing Extremity Ulcers.

Rica Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.